Home / Business and Economy / Parabilis Aims for $475M IPO with Novel Peptide Therapies
Parabilis Aims for $475M IPO with Novel Peptide Therapies
5 Jun
Summary
- Parabilis Medicines plans to raise up to $475 million in its US IPO.
- The company develops Helicons, a new class of stabilized helical peptides.
- Shares will trade on Nasdaq under the ticker symbol PBLS after closing.
Parabilis Medicines, a clinical-stage biopharmaceutical firm, is aiming to secure up to $475 million from its U.S. initial public offering. The company is leveraging a proprietary platform to develop Helicons, a distinct class of stabilized helical peptides.
These novel peptides are engineered to target and modulate proteins that have historically presented challenges for conventional drug development. Parabilis intends to offer 25 million shares, with pricing anticipated to be between $17 and $19 per share.
Upon the successful conclusion of the offering, Parabilis's stock is slated to commence trading on the Nasdaq stock exchange. The company will be accessible to investors under the ticker symbol "PBLS".
